ESCROW SERVICES AGREEMENT ENHANCED SERVICESEscrow Services Agreement • April 28th, 2020 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • Nevada
This Escrow Services Agreement (this “Agreement”) is made and entered into as of July 26, 2019 by and between Prime Trust, LLC (“Prime Trust” or “Escrow Agent”) and Emerald Health Pharmaceuticals Inc. (“Issuer”).
Broker-Dealer AgreementBroker-Dealer Agreement • October 6th, 2021 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Emerald Health Pharmaceuticals Inc. (“Client”), a Delaware Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of October 4, 2021 (the “Effective Date”):
Indemnification AgreementIndemnification Agreement • March 5th, 2018 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made and entered into as of [DATE] (the “Effective Date”) by and between Emerald Health Pharmaceuticals Inc., a Delaware corporation (the “Company”), and [INDEMNITEE NAME] (the “Indemnitee”).
SUBSCRIPTION AGREEMENTSubscription Agreement • March 5th, 2018 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
THIS SUBSCRIPTION AGREEMENT (this “Agreement” or this “Subscription”) is made and entered into as of ______________, by and between the undersigned (the “Subscriber”) and Emerald Health Pharmaceuticals Inc., a Delaware corporation (“Emerald Pharmaceuticals”), with reference to the facts set forth below.
INDEPENDENT CONTRACTOR SERVICES AGREEMENTIndependent Contractor Services Agreement • December 9th, 2019 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • California
This Independent Contractor Services Agreement (this “Agreement”) effective as of December 1, 2019 (the “Effective Date”), is entered into between Emerald Health Pharmaceuticals Inc., a Delaware corporation (“Company”), and Dr. Avtar Dhillon, an individual (“Contractor”). The parties hereby agree as follows:
LOAN AGREEMENTLoan Agreement • March 5th, 2018 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations
EMERALD HEALTH SCIENCES INC., a corporation incorporated under the laws of British Columbia with an office at 200-375 Water St. Vancouver, BC, V6B 0M9
Board Observer AgreementBoard Observer Agreement • November 21st, 2019 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
EMERALD HEALTH PHARMACEUTICALS INC., a corporation incorporated under the laws of Delaware, and having its office at 5910 Pacific Center Blvd, Ste 300, San Diego, CA 92121 (the “Corporation”)
INDEPENDENT CONTRACTOR AGREEMENTIndependent Contractor Agreement • September 30th, 2019 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • British Columbia
EMERALD HEALTH PHARMACEUTICALS INC., a corporation incorporated under the laws of Delaware, and having its registered office at New Burton Road, #201, Dover, Kent County, Delaware
LOAN TERMINATION AGREEMENTLoan Termination Agreement • July 26th, 2021 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • British Columbia
EMERALD HEALTH SCIENCES INC., a corporation incorporated under the laws of British Columbia with a registered office at 2500-666 Burrard Street, Vancouver, BC
Broker-Dealer AgreementBroker-Dealer Agreement • September 30th, 2019 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Emerald Health Pharmaceuticals Inc. (“Client”) a Delaware Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective of June 20th, 2019 (the “Effective Date”):
EMERALD HEALTH PHARMACEUTICALS INC.Executive Employment Agreement • September 30th, 2019 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations
This Executive Employment Agreement (the “Agreement”), dated [__________], 2019, is between [_______] (the “Company”) and [_______] (“Executive”) in the position of Chief [__________________] Officer, effective [________________], 2019. You will report directly to the [Chief Executive Officer] [Board of Directors], and devote your full productive time to performing services to the Company.
Emerald Health Pharmaceuticals Inc. CONSULTING AGREEMENTConsulting Agreement • September 30th, 2022 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • California
This Consulting Agreement ("Agreement") is made and entered into as of September 1, 2022, by and between Emerald Health Pharmaceuticals Inc. ("Company"), and Kranz & Associates Holdings, LLC, a Delaware limited liability company ("Consultant"). Company desires to retain Consultant as an independent contractor to perform consulting services for Company, and Consultant is willing to perform such services, on terms set forth more fully below. In consideration of the mutual promises contained herein, the parties agree as follows:
COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • March 5th, 2018 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • British Columbia
VCE-004: All new uses of cannabinoid derivatives of the Series 4 that would be technical subject matter that is not excluded from patentability based on the chemical backbone described below, and including the embodiments described below.
CONSULTING AGREEMENT Córdoba, <@> May 2017 MEETING OF THE PARTIESConsulting Agreement • March 5th, 2018 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
OF A PART: D. Eduardo Muñoz Blanco of legal age, with ID 30448749S, and with N.R.P. 3044874924A0500, Professor of Immunology, belonging to the Department of Cellular Biology, Physiology and Immunology of the University of Cordoba, acting on behalf of the latter by virtue of the authorization granted to sign this contract dated XX-05-2017 in accordance with the provisions of Article 83 of Organic Law 6/2001 of Universities, of December 21, and in articles 142 to 144 of the statutes of the University of Córdoba
CONSULTING AGREEMENTConsulting Agreement • September 30th, 2022 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • British Columbia
WITNESSES THAT WHEREAS on July 8, 2022, the CEO and CFO of Emerald voluntarily resigned as they were in the process of negotiating a settlement with the Securities and Exchange Commission;
SUBSCRIPTION AGREEMENTSubscription Agreement • March 29th, 2019 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
THIS SUBSCRIPTION AGREEMENT (this “Agreement” or this “Subscription”) is made and entered into as of _______________, by and between the undersigned (the “Subscriber”) and Emerald Health Pharmaceuticals Inc., a Delaware corporation (“Emerald Pharmaceuticals”), with reference to the facts set forth below.
CONSULTING AGREEMENTConsulting Agreement • September 28th, 2020 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • California
THIS CONSULTING AGREEMENT (the “Agreement”), is made and entered into as of July 31, 2020 (the “Effective Date”), by and among EMERALD HEALTH PHARMACEUTICALS INC., a United States corporation organized under the laws of the State of Delaware (the “Company”); BERI HOLDINGS, LLC, a United States limited liability company organized under the laws of the State of Florida (the “Consultant”) and the Consultant’s Executive Manager, AMIT RAJ BERI, an individual (hereinafter referred to as the “Executive”).
AMENDMENT AGREEMENTLoan Agreement • March 5th, 2018 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations
EMERALD HEALTH SCIENCES INC., a corporation incorporated under the laws of British Columbia with an office at 200-375 Water St. Vancouver, BC, V6B 0M9
Intellectual Property Transfer AgreementIntellectual Property Transfer Agreement • March 5th, 2018 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
VCE-004: All new uses of cannabinoid derivatives of the VCE-004 series that would be technical subject matter that is not excluded from patentability based on the chemical backbone described below, and including the embodiments described below.
AMENDMENT AGREEMENT NO. 2Amendment Agreement • November 21st, 2019 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations
EMERALD HEALTH SCIENCES INC., a corporation incorporated under the laws of British Columbia with an office at 2500 Park Place (c/o- Bennett Jones LLP), 2500 Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8
FIRST AMENDMENT TO LEASE (5910 Pacific Center)Lease • September 28th, 2020 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this "Amendment") is made and entered into as of July 14, 2019, by and between G&I VIII SORRENTO LP, a Delaware limited partnership ("Landlord") and EMERALD HEALTH PHARMACEUTICALS INC., a Delaware corporation ("Tenant").
ContractAmendment Agreement • July 28th, 2022 • Emerald Health Pharmaceuticals Inc. • Pharmaceutical preparations
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the company treats as private or confidential. Such portions are marked as indicated with [***].
